DIA会员及用户请点击登录

登录

忘记用户 ID? or 忘记密码?

Not a Member?

创建账户并加入。

Walter E. Washington Convention Center

2015 年 06 月 14 日 2:30 下午 - 2015 年 06 月 18 日 6:45 下午

801 Mount Vernon Place, NW, , Washington, DC 20001-3614 , USA

DIA 2015 51st Annual Meeting: Develop. Innovate. Advance.

Full conference and one-day registrants will have access to presentation PDFs through Friday, December 18, 2015 <A href="http://www.diaglobal.org/Flagship-Meetings/DIA-Annual-Meeting/Meeting-Program/ePac-Presentations-Access.aspx">Review Presentations </A>

Managing Protocol Deviations: Applying the Protocol Deviations Working Group SOP for Handling Protocol Deviations in Clinical Trials

Session Chair(s)

Maryrose  Petrizzo, MS

Maryrose Petrizzo, MS

President and Consultant

Clinical Quality Assured,LLC, United States

This workshop will provide a sample clinical trial protocol and corresponding protocol deviation handling plan (PDHP) along with the standard operating procedure (SOP) and protocol deviations reporting form. Several protocol deviations (PD) will be provided and workshop attendees will be asked to follow the PDHP to handle the classification and reporting of the PD.

This workshop was developed by the DIA Good Clinical Practice and Quality Assurance Community and the Protocol Deviations Working Group.

**Due to workshop format, seating will be limited and will be available on a first come, first served basis.

The Walter E. Washington Convention Center has stringent regulations on maximum room capacities, and they are strictly enforced. Once all seats are occupied, DIA will be required to close the workshop, and no more participants will be admitted. Interested attendees are encouraged to arrive at workshops early in order to ensure seating. Please note, as a workshop with interactivity, this offering will not be recorded.

Learning Objective : Review the sample protocol, standard operating procedure (SOP) and corresponding protocol deviations handling plan and tracking form; Apply the SOP and PDHP to protocol deviations reported during the sample trial; Review if any changes are required to the SOP, template or form and any next steps to increasing adoption in industry to the proposed SOP, template and form.

Speaker(s)

Munish  Mehra, PhD, MS, MSc

Facilitator

Munish Mehra, PhD, MS, MSc

Quantum Biopharma, United States

Managing Director and Sr. Principal Biostatistician

Sandy  Mohan, PhD

Facilitator

Sandy Mohan, PhD

Immune Design, United States

Vice President, Quality and Compliance

注册方法

Registration override should work.

获得信息并保持参与

不要错失任何机会——请加入我们的邮件列表,了解DIA的观点和事件。